Gemcitabine: A Critical Nucleoside for Cancer Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|19|7|1076-1087

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.19, Iss.7, 2012-03, pp. : 1076-1087

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine

By Muggia Franco   Diaz Isabela   Peters Godefridus J  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 4, 2012-04 ,pp. : 403-408

Informa Healthcare

Access to resources Recommend Favorite

Combination gemcitabine + cisplatin therapy for recurrent ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1376, 2003-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?

By Pectasides Dimitris   Psyrri Amanda   Pectasides Melina   Economopoulos Theofanis  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 8, 2006-06 ,pp. : 975-987

Informa Healthcare

Access to resources Recommend Favorite

Combination therapy with gemcitabine and docetaxel is effective in patients with advanced urothelial cancer

By  

Inpharma, Vol. 1, Iss. 1416, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)

By  

Current Cancer Drug Targets, Vol. 11, Iss. 1, 2011-01 ,pp. : 123-129

Bentham Science Publishers

Access to resources Recommend Favorite